ArticleFrontiers in immunology2026
Immune dysregulation drives the relapse of peritoneal dialysis-associated peritonitis: a single-center prospective study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The diagnosis and management of relapsing peritoneal dialysis-associated peritonitis (PDAP) remains a clinical challenge. This study aimed to identify biomarkers associated with relapsing PDAP and discuss potential mechanisms. Methods: 31 PDAP patients treated in 2023 were prospectively enrolled, including 23 cured patients and 8 with relapsing PDAP. Peritoneal dialysate samples were collected for conventional bacterial culture, 16S rDNA sequencing, and proteomic analysis. Results: The positivity rate for conventional culture was 64.5%, while that for 16S rDNA sequencing was 67.8%; combining both methods increased the detection rate to 83.9%. Microbiome analysis revealed that PDAP relapse may stem not only from exogenous pathogens but also from gut-derived bacterial translocation due to impaired local immunity. Proteomic profiling revealed that compared with the Cured group, the Relapse group showed downregulated levels of CCL28, CD40, and uPA, and upregulated NRTN. Bioinformatic analysis revealed dysregulation in pathways related to inflammation, fibrinolysis, and immune clearance, thus linking relapsing PDAP to a disturbed peritoneal immune microenvironment. Conclusion: Relapsing PDAP is linked to peritoneal immune dysregulation, and 16S rDNA sequencing represents a complementary diagnostic tool. These findings may guide precise management and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.